Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol.
Serum analysis carried out about 7 days before menstruation in 33 patients with mastodynia and 20 controls confirmed that progesterone is frequently decreased and prolactinaemia increased in the patients with mastodynia compared with controls of the same age. In a double blind trial, administration of Lynestrenol to 47 patients with mastodynia (each of whom was given 10 mg per day from the 10th to the 24th day of the cycle) resulted in a significant improvement of this condition in 80% of the treated cases. The therapeutic failures may be explained by anomalies in the secretion of prolactin, and may possibly be linked to individual sensitivity factors.
D000328:Adult; D001941:Breast Diseases / Q000175:diagnosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000627:therapeutic use*; D008598:Menstruation; D010146:Pain / Q000188:drug therapy; D010919:Placebos; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D013817:Thermography; D013997:Time Factors
D010919:Placebos; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D008234:Lynestrenol